Abstracts tagged "Autoinflammatory diseases"

Abstract Number: 0130 • ACR Convergence 2022
Three Chinese Pedigrees of A20 Haploinsufficiency
Yi Tian¹, Min Shen², Bingxuan Wu², linyi Peng² and Jian Wang³, ¹Rheumatology Department, The Second Affiliated Hospital of Dalian Medical University, Dalian, China, ²Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ³Jinzhou City Center for Disease Control and Prevention, Jinzhou, China
Background/Purpose: Haploinsufficiency of A20 (HA20) is a newly described rare autoinflammatory disease caused by TNFAIP3 gene mutations. HA20 has been seldom documented in the Chinese…
Abstract Number: 0791 • ACR Convergence 2022
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Ingrid Egeland Christensen¹, Siri Mjaaland², David Warren³, Tore K. kvien¹, Kristin Hammersbøen Bjørlykke⁴, Grete Birkeland Kro³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Sella Aarrestad Provan¹, Kristin Kaasen Jørgensen⁴, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…
Abstract Number: 1698 • ACR Convergence 2022
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
Daniel Rios¹, Nafeeza Hafeez¹, Brian Desrosiers¹, Shradha Rao¹, Jess Floro¹, Joelle Baddour¹, Nisha Perez², Greg Bisacchi², Oliver Saunders², Donna Romero¹, Menachem Fromer², Enrique Garcia-Rivera², Wilson McKerrow², Julie Behr², Bryan Thornlow², Dennis Zaller², David Proia² and Wenyan Miao², ¹Rome Therapeutics, Cambridge, MA, ²Rome Tx, Cambridge, MA
Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs…
Abstract Number: 2101 • ACR Convergence 2022
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Ekrem Turk, Vaishali Deenadayalan, Khaldun Obeidat and Pierre Rodriguez, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
Abstract Number: 0134 • ACR Convergence 2022
Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A
Francesco Ferro¹, Elena Elefante², Italiano Nazzareno², Gaetano La Rocca³, Davide Schilirò², Michele Moretti², Roberto Mozzo⁴, De Simone Luigi⁴, Chiara Baldini⁵ and Marta Mosca², ¹Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ⁴Anesthesiology & Intensive Care Unit/Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Growing evidence from RCTs and real-life experiences has highlighted important similarities between severe COVID19 and rapidly progressive interstitial lung diseases (RP-ILD) occurring in connective…
Abstract Number: 0812 • ACR Convergence 2022
3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry
Jasmin B. Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Prasad T. Oommen³, Ales Janda⁴, Juergen Rech⁵, Catharina Schuetz⁶, Tilmann Kallinich⁷, Frank Weller-Heinemann⁸, Gerd Horneff⁹, Ivan Foeldvari¹⁰, Florian Meier¹¹, Michael Borte¹², Tobias Krickau¹³, Julia Weber-Arden¹⁴ and Norbert Blank¹⁵, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Division of Nephrology, University of Marburg, Marburg, Germany, ³Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴Department of Pediatrics, University Hospital Ulm, Ulm, Germany, ⁵University Clinic Erlangen, Erlangen, Germany, ⁶Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, ⁷Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁸Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ⁹Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ¹⁰Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹¹Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ¹²ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, ¹³Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ¹⁴Novartis Pharma GmbH, Nuernberg, Germany, ¹⁵Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Cryopyrin-associated periodic syndromes (CAPS) are monogenic autoinflammatory diseases with severe systemic inflammation. The IL-1β inhibitor canakinumab (CAN) leads to a rapid remission of CAPS…
Abstract Number: 1701 • ACR Convergence 2022
High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology
Patricia Pontes Aires¹, André Cunha¹, DANIELA GERENT PETRY PIOTTO¹, Maria Teresa Terreri² and Sandro Perazzio¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidad Federal São Paulo, São Paulo, Brazil
Background/Purpose: A20 haploinsufficiency (A20HA), an important monogenic etiology of Behçet's disease (BD), is caused by loss-of-function mutations in TNFAIP3. Although monocytes play an important role…
Abstract Number: 2194 • ACR Convergence 2022
Is Vaccination Against Covid-19 Associated with Autoimmune Rheumatic Disease Flare? Self-controlled Case Series Analysis Using Data from the Clinical Practice Research Datalink (Aurum)
Georgina Nakafero¹, Matthew J. Grainge¹, Tim Card¹, Christian Mallen², Jonathan S. Nguyen van Tam¹, Hywel C. Williams¹ and Abhishek Abhishek¹, ¹University of Nottingham, Nottingham, United Kingdom, ²Keele University, Keele, United Kingdom
Background/Purpose: It is unclear whether autoimmune rheumatic disease (AIRD) flares are associated with the recent prior Covid-19 vaccination, and whether the association was influenced by…
Abstract Number: 0138 • ACR Convergence 2022
Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
Joerg Henes¹, Jasmin B. Kuemmerle-Deschner², Tobias Krickau³, Tilmann Kallinich⁴, Frank Dressler⁵, Gerd Horneff⁶, Florian Meier⁷, Ivan Foeldvari⁸, Frank Weller-Heinemann⁹, Birgit Kortus-Goetze¹⁰, Markus Hufnagel¹¹, Juergen Rech¹², Prasad T. Oommen¹³, Julia Weber-Arden¹⁴ and Norbert Blank¹⁵, ¹Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ²Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ³Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁶Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁷Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ⁸Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁹Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ¹⁰Division of Nephrology, University of Marburg, Marburg, Germany, ¹¹Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹²University Clinic Erlangen, Erlangen, Germany, ¹³Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹⁴Novartis Pharma GmbH, Nuernberg, Germany, ¹⁵Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Familial Mediterranean fever (FMF) is a chronic disease characterized by recurrent episodes of fever and serositis, with a risk of severe complications (e. g.…
Abstract Number: 0813 • ACR Convergence 2022
Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis
Norbert Blank¹, Catharina Schuetz², Joerg Henes³, Tilmann Kallinich⁴, Prasad T. Oommen⁵, Michael Borte⁶, Markus Hufnagel⁷, Ales Janda⁸, Julia Weber-Arden⁹ and Jasmin B. Kuemmerle-Deschner¹⁰, ¹Rheumatology, University Hospital Heidelberg, Heidelberg, Germany, ²Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, ³Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁶ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, ⁷Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁸Department of Pediatrics, University Hospital Ulm, Ulm, Germany, ⁹Novartis Pharma GmbH, Nuernberg, Germany, ¹⁰Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany
Background/Purpose: TRAPS is a rare hereditary autoinflammatory disease characterized by periodic fever and severe systemic and organ inflammation. Successful treatment was achieved with the interleukin-1β…
Abstract Number: 1721 • ACR Convergence 2022
Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome
Christine Rysenga¹, Linda May-Zhang², Miela Zahavi³, Jason S Knight⁴ and Ramadan Ali¹, ¹University of Michigan, Ann Arbor, MI, ²Blue California, Rancho Santa Margarita, CA, ³Universtiy of Michigan, Ann Arbor, MI, ⁴University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Taxifolin, also known as dihydroquercetin, is a bioactive flavonoid commonly found in apples, onions, French maritime bark, and milk thistle. Given its potent anti-inflammatory…
Abstract Number: 2209 • ACR Convergence 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
Hermine Brunner¹, Elena Chertok², Joke Dehoorne³, Gerd Horneff⁴, Tilmann Kallinich⁵, Ingrid Louw⁶, Maria Alessio⁷, Sandrine Compeyrot-Lacassagne⁸, Bernard Lauwerys⁹, Neil Martin¹⁰, Katherine Marzan¹¹, W Patrick Knibbe¹², Ruvie Martin¹³, Xuan Zhu¹⁴, sarah whelan¹⁵, Luminita Pricop¹⁶, Daniel Lovell¹⁷, Alberto Martini¹⁸ and Nicola Ruperto¹⁹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ²Voronezh State Medical University, Voronezh, Russia, ³University Hospital Gent, Gent, Belgium, ⁴Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁵Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁶Panaroma Medical Centre, Cape Town, South Africa, ⁷Policlinico Federico II di Napoli, Napoli, Italy, ⁸Great Ormond Street Hospital for Children, London, United Kingdom, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Royal Hospital for Children, Glasgow, Scotland, United Kingdom, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²St. Luke's Hospital System, Meridian, ID, ¹³Novartis Pharmaceutical Corporation, East Hanover, NJ, ¹⁴Novartis Pharmaceuticals Corporation, Basking Ridge, NJ, ¹⁵Novartis Ireland Ltd, Crumlin, Dublin, Ireland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁸Istituto Giannina Gaslini, Genova, Italy, ¹⁹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) represent pediatric counterparts of adult non-radiographic axial spondyloarthritis and psoriatic…
Abstract Number: 0139 • ACR Convergence 2022
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Steven Feldman¹, Heimo stroissnig², Richard Kay³, Joanna Sobierska⁴, Roshan Dias⁴, Eric Guenzi⁵, Hendrik Otto², Halimuniyazi Haliduola², Abid Sattar⁶, Ruth Ruffieux⁴, Matjaz Steijger⁴ and Fausto Berti⁴, ¹Wake Forest School of Medicine, Winston-Salem, NC, ²Alvotech, Jülich, Germany, ³RK Statistics, Bakewell, United Kingdom, ⁴Alvotech, Zürich, Switzerland, ⁵UGA Biopharma, Bonn, Germany, ⁶Alvotech, London, United Kingdom
Background/Purpose: To support a demonstration of interchangeability of proposed biosimilar AVT02 and Humira® (reference adalimumab).Methods: Participants with chronic plaque psoriasis were selected for the study…
Abstract Number: 0815 • ACR Convergence 2022
Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease
Brianne Navetta-Modrov and QingPing Yao, Stony Brook University, Stony Brook, NY
Background/Purpose: Hyper-immunoglobulin G4 (IgG4) has been reported in various conditions including autoimmune disease, gastrointestinal disorders, lymphoproliferative/granulomatous diseases and solid tumors. IgG4-related disease is an immune-mediated…
Abstract Number: 1741 • ACR Convergence 2022
Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model
Leah Huey¹, Kylie Koney¹, Emily Vance¹, Chia-Feng Tsai², Rosalie K. Chu², Marina A. Gritsenko², Ellen Lee¹, Holly Rosenzweig¹ and Ruth Napier¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR, ²Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA
Background/Purpose: Mutations in the microbial signaling molecule NOD2 cause granulomatous uveitis, arthritis, and dermatitis in Blau Syndrome. We previously showed a novel role for Nod2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].